Impact of metabolic syndrome on in-stent restenosis and clinical outcomes after percutaneous coronary stent implantation

Effect of angiotensin converting enzyme inhibitors on periprocedural myocardial infarction in patients with metabolic syndrome

“…Existing studies have yielded inconsistent data on whether MetS increases the risk of cardiovascular events after PCI [15][16][17][18]. However, a recent meta-analysis stated MetS as an important risk factor following stent implantation [5].…”

Risk of major adverse cardiovascular events in patients with metabolic syndrome after revascularization: A meta-analysis of eighteen cohorts with 18457 patients

“…Duplicate publications could introduce substantial bias, thus only one or two of them, without duplicate participants, were available in the individual meta-analysis. Among the included studies, the followups varied from one to twelve years, and four [9,11,22,24] were retrospective cohorts. Studies were published between 2005 and 2014, with sample sizes varying from 157 to 6352.…”

“…Studies were published between 2005 and 2014, with sample sizes varying from 157 to 6352. Ten trials [10][11][12][14][15][16][17]19,20,[23][24][25]28] were performed in eastern countries (China, Japan, and Korea) and the remaining [9,13,18,21,22,26,27,29] in western countries (Italy, USA, Germany, Greece, and Brazil). Of these trials, three of them with four publications [12,16,21,27] were conducted in patients without DM.…”

“…MetS was reported to be associated with increased risks of type 2 diabetes mellitus (DM), cardiovascular and cerebrovascular events, and chronic kidney disease (CKD) [5][6][7][8]. Several studies [9][10][11][12][13][14][15][16][17][18][19][20] have reported that MetS is an independent risk factor of major adverse cardiovascular events (MACE) in patients with CAD undergoing revascularization, nevertheless, some others indicate that no impact [21][22][23][24][25][26][27][28] and even protective effect [29] of MetS exists in these patients.…”

Impact of metabolic syndrome on the outcomes of superficial femoral artery interventions

“…The presence of obesity and MetSyn significantly increased the risks of subsequent cardiac events among patients who underwent percutaneous coronary intervention. [36][37][38][39][40] Similar poor functional outcomes have been seen after renal interventions in patients with MetSyn. 12 Patients with MetSyn had an overall poorer clinical efficacy (freedom from recurrent symptoms, maintenance of ambulation, and absence of a major amputation) than those without MetSyn.…”